Get started
Author

Akihiro Tsukaguchi

Observed names: A. Tsukaguchi, A., Tsukaguchi, AKIHIRO TSUKAGUCHI
ORCID: 0009-0009-6296-4386
Observed ORCID: 0009-0009-6296-4386
OpenAlex ID: A5037841508
Timing of first pembrolizumab infusion and long-term outcomes in non-small cell lung cancer: A retrospective multicenter study
2025 · Akihiro Tsukaguchi, Kinnosuke Matsumoto, et al. · European Journal of Cancer · 17
Real‐World Efficacy and Safety of Lenvatinib in Advanced or Recurrent Thymic Carcinoma: A Multicenter Retrospective Study in Japan
2025 · Satoshi Miyamoto, Akihiro Tsukaguchi, et al. · Thoracic Cancer · 7
PDF
Lenvatinib-refractory thymic mucinous carcinoma with PIK3CA mutation
2022 · Akihiro Tsukaguchi, Shoichi Ihara, et al. · International Cancer Conference Journal · 5
672P Association between the administration time and therapeutic effect of nivolumab in patients with non-small cell lung cancer: A multicenter retrospective observational study
2024 · Y. Iwahashi, A. Tamiya, et al. · Annals of Oncology · 4
PDF
Concurrent Nivolumab-Induced Gastritis and Cholangitis Accompanied by Biliary Tract Hemorrhage in a Patient With Stage IV Lung Adenocarcinoma
2023 · Akihiro Tsukaguchi, Norihiko Yamaguchi, et al. · Cureus · 4
PDF
Successful Dasatinib Treatment of Epidermal Growth Factor Receptor-Mutant Lung Adenocarcinoma and BCR-ABL1-Positive Chronic Myeloid Leukemia: A Case Report
2022 · Akihiro Tsukaguchi, Seigo Minami, et al. · Case Reports in Oncology · 4
Association Between Administration Timing and Efficacy of Nivolumab in Non-small Cell Lung Cancer Treatment
2025 · YUKI IWAHASHI, AKIHIRO TAMIYA, et al. · Anticancer Research · 2
A Multicenter, Retrospective, Real-World Study of Atezolizumab Plus Chemotherapy and Pembrolizumab Plus Chemotherapy for Older Patients With NSCLC
2025 · Kensuke Kanaoka, Kinnosuke Matsumoto, et al. · JTO Clinical and Research Reports · 2
PDF
Real-world Data of the Lung Cancer Compact Panel™ in Non-small Cell Lung Cancer Using Tissue Samples
2025 · YOSHIHIKO TANIGUCHI, AKIHIRO TAMIYA, et al. · Anticancer Research · 2
Impact of preexisting interstitial lung disease on pneumonitis and survival during first-line immune checkpoint inhibitor-based therapy in non-small cell lung cancer
2026 · Kinnosuke Matsumoto, Yuji Yamamoto, et al. · European Journal of Cancer · 1
PDF
Systemic Inflammation Modifies the Efficacy of Bevacizumab Added to Atezolizumab Plus Chemotherapy for Advanced Non‐Squamous Non‐Small Cell Lung Cancer: A Multicenter Retrospective Study
2026 · Keijiro Yamauchi, Kinnosuke Matsumoto, et al. · Thoracic Cancer · 1
Successful Treatment with Surgical Resection for Nocardia cyriacigeorgica Infection in Pulmonary Sequestration
2026 · Akihiro Tsukaguchi, Takafumi Iguchi, et al. · Internal Medicine · 1
PDF
Multicenter retrospective study of selpercatinib treatment for advanced or recurrent RET fusion-positive non-small cell lung cancer in Japan
2025 · Yasuhiro Mihashi, Kiyohide Komuta, et al. · Investigational New Drugs · 1
Corrigendum to “Timing of first pembrolizumab infusion and long-term outcomes in non-small cell lung cancer: A retrospective multicenter study” [Eur J Cancer. 2025;228:115748]
2025 · Akihiro Tsukaguchi, Kinnosuke Matsumoto, et al. · European Journal of Cancer · 1
PDF
1997P Comparative effectiveness of first-line MET tyrosine kinase inhibitors versus Immune checkpoint inhibitors with or without chemotherapy in advanced non-small cell lung cancer with MET exon 14 skipping mutation: A multicenter retrospective study in Japan
2025 · K. Komuta, K. Kunimasa, et al. · Annals of Oncology · 1
Case of a rare EGFR mutation L747P identified using the lung cancer compact Panel™ leading to successful Afatinib treatment
2025 · Hitoshi Sumitani, Akihiro Tamiya, et al. · Respiratory Medicine Case Reports · 1
Safety and Efficacy of Durvalumab After Chemoradiotherapy in Antinuclear Antibody-positive Patients With Non-small Cell Lung Cancer
2024 · AKIHIRO TSUKAGUCHI, AKIHIRO TAMIYA, et al. · Anticancer Research · 1
First-line MET inhibitors versus immune checkpoint inhibitor–based regimens in MET exon 14 skipping mutation positive NSCLC: a multicenter real-world cohort study in Japan
2026 · K. Komuta, K. Kunimasa, et al. · ESMO rare cancers.
PDF
Impact of pre-existing interstitial lung abnormalities on pneumonitis risk and survival in chemo-naive patients with non-small-cell lung cancer receiving pembrolizumab plus chemotherapy
2026 · Hirotomo Machiyama, Kinnosuke Matsumoto, et al. · Respiratory Medicine
Clinical Outcomes of First-Line Pembrolizumab Monotherapy in Advanced NSCLC With PD-L1 Tumor Proportion Score of 1% to 49%: A Retrospective Multicenter Study
2026 · Akito Miyazaki, Kinnosuke Matsumoto, et al. · JTO Clinical and Research Reports
PDF
Mycobacterium brisbanense Pulmonary Disease Treated with a Macrolide-Based Multidrug Regimen: A Case Report
2026 · Yuki Nakaya, Kazuki Hashimoto, et al. · Internal Medicine
PDF
Long-term survival comparison of first-line pembrolizumab versus pembrolizumab plus chemotherapy for patients with advanced non-small cell lung cancer: A multicenter propensity-matched cohort study
2025 · Nao Shoshihara, Kinnosuke Matsumoto, et al. · Lung Cancer
PDF
EP.08F.08 Safety and Efficacy of Durvalumab Consolidation Therapy after Chemoradiotherapy in NSCLC Patients Positive for Antinuclear Antibodies
2024 · A. Tsukaguchi, A. Tamiya, et al. · Journal of Thoracic Oncology
PDF
Supplementary Material for: Successful Dasatinib Treatment of Epidermal Growth Factor Receptor Mutant Lung Adenocarcinoma and BCR-ABL1-Positive Chronic Myeloid Leukemia: A Case Report
2022 · A., Tsukaguchi, S., Minami, et al. · Figshare
Works count: 24
Citation count: 55
H-index: 4
I10-index: 1
Year
Topic
Type